Advanced search
Publication Cover
mAbs Volume 4, 2012 - Issue 1
Submit an article Journal homepage
3,380
Views
58
CrossRef citations to date
0
Altmetric
Report

Subcutaneous bioavailability of therapeutic antibodies as a function 
of FcRn binding affinity in mice

Rong Deng Genentech Inc.; South San Francisco, CA USA; Department of Pharmacokinetic and Pharmacodynamic SciencesCorrespondence[email protected]
,
Y. Gloria Meng Genentech Inc.; South San Francisco, CA USA; Department of Assay & Automation Technology
,
Kwame Hoyte Genentech Inc.; South San Francisco, CA USA; Department of Assay & Automation Technology
,
Jeff Lutman Genentech Inc.; South San Francisco, CA USA; Department of Pharmacokinetic and Pharmacodynamic Sciences
,
Yanmei Lu Genentech Inc.; South San Francisco, CA USA; Department of Assay & Automation Technology
,
Suhasini Iyer Genentech Inc.; South San Francisco, CA USA; Department of Pharmacokinetic and Pharmacodynamic Sciences
,
Laura E DeForge Genentech Inc.; South San Francisco, CA USA; Department of Assay & Automation Technology
,
Frank-Peter Theil Genentech Inc.; South San Francisco, CA USA; Department of Pharmacokinetic and Pharmacodynamic Sciences
,
Paul J. Fielder Genentech Inc.; South San Francisco, CA USA; Department of Pharmacokinetic and Pharmacodynamic Sciences
&
Saileta Prabhu Genentech Inc.; South San Francisco, CA USA; Department of Pharmacokinetic and Pharmacodynamic Sciences
 show all
Pages 101-109 | Received 07 Sep 2011, Accepted 26 Oct 2011, Published online: 01 Jan 2012

Citations (58)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (7)

Wolfgang F. Richter, Gregory J. Christianson, Nicolas Frances, Hans Peter Grimm, Gabriele Proetzel & Derry C. Roopenian. (2018) Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice. mAbs 10:5, pages 803-813.
Read now
Paul Malik & Andrea Edginton. (2018) Pediatric physiology in relation to the pharmacokinetics of monoclonal antibodies. Expert Opinion on Drug Metabolism & Toxicology 14:6, pages 585-599.
Read now
Charlotte Bon, Thomas Hofer, Alain Bousquet-Mélou, Mark R. Davies & Ben-Fillippo Krippendorff. (2017) Capacity limits of asialoglycoprotein receptor-mediated liver targeting. mAbs 9:8, pages 1360-1369.
Read now
Jay Tibbitts, David Canter, Ryan Graff, Alison Smith & Leslie A. Khawli. (2016) Key factors influencing ADME properties of therapeutic proteins: A need for ADME characterization in drug discovery and development. mAbs 8:2, pages 229-245.
Read now
Céline Monnet, Sylvie Jorieux, Nathalie Souyris, Ouafa Zaki, Alexandra Jacquet, Nathalie Fournier, Fabien Crozet, Christophe de Romeuf, Khalil Bouayadi, Rémi Urbain, Christian K Behrens, Philippe Mondon & Alexandre Fontayne. (2014) Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. mAbs 6:2, pages 422-436.
Read now
Nancy Chen, Weirong Wang, Scott Fauty, Yulin Fang, Lora Hamuro, Azher Hussain & Thomayant Prueksaritanont. (2014) The effect of the neonatal Fc receptor on human IgG biodistribution in mice. mAbs 6:2, pages 502-508.
Read now
Josée Golay, Gianpietro Semenzato, Alessandro Rambaldi, Robin Foà, Gianluca Gaidano, Enrica Gamba, Fabrizio Pane, Antonello Pinto, Giorgina Specchia, Francesco Zaja & Mario Regazzi. (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. mAbs 5:6, pages 826-837.
Read now

Articles from other publishers (51)

Alexander M. Curreri, Jayoung Kim, Michael Dunne, Pavimol Angsantikul, Morgan Goetz, Yongsheng Gao & Samir Mitragotri. (2023) Deep Eutectic Solvents for Subcutaneous Delivery of Protein Therapeutics. Advanced Science 10:7, pages 2205389.
Crossref
Shihao Hu, Amita Datta-Mannan & David Z. D’Argenio. (2022) Monoclonal Antibody Pharmacokinetics in Cynomolgus Monkeys Following Subcutaneous Administration: Physiologically Based Model Predictions from Physiochemical Properties. The AAPS Journal 25:1.
Crossref
Yujia Zhai, Shuyun Dong, Haojia Li, Yue Zhang, Paul Shami & Mingnan Chen. (2022) Antibody-mediated depletion of programmed death 1-positive (PD-1+) cells. Journal of Controlled Release 349, pages 425-433.
Crossref
Shufang Liu & Dhaval K. Shah. (2022) Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics. Drug Metabolism and Disposition 50:6, pages 867-878.
Crossref
Ilse R. Dubbelboer & Erik Sjögren. (2022) Physiological based pharmacokinetic and biopharmaceutics modelling of subcutaneously administered compounds – An overview of in silico models. International Journal of Pharmaceutics 621, pages 121808.
Crossref
Eric Salgado & Yanguang Cao. (2022) A Physiologically Based Pharmacokinetic Framework for Quantifying Antibody Distribution Gradients from Tumors to Tumor-Draining Lymph Nodes. Antibodies 11:2, pages 28.
Crossref
Paul R. V. Malik, Abdullah Hamadeh & Andrea N. Edginton. (2022) Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies. Pharmaceutical Research 39:2, pages 239-250.
Crossref
Jurij Hanzel, Laura H. Bukkems, Krisztina B. Gecse, Geert R. D’Haens & Ron A. A. Mathôt. (2021) Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis. Alimentary Pharmacology & Therapeutics 54:10, pages 1309-1319.
Crossref
Rodney R. Walters, Joseph F. Boucher & Flavia De Toni. (2021) Pharmacokinetics and Immunogenicity of Frunevetmab in Osteoarthritic Cats Following Intravenous and Subcutaneous Administration. Frontiers in Veterinary Science 8.
Crossref
Zhe Li, Xiaoying Yu, Yingyi Li, Ashwni Verma, Hsuan Ping Chang & Dhaval K. Shah. (2021) A Two-Pore Physiologically Based Pharmacokinetic Model to Predict Subcutaneously Administered Different-Size Antibody/Antibody Fragments. The AAPS Journal 23:3.
Crossref
Roberta Fenoglio, Simone Baldovino, Savino Sciascia, Emanuele De Simone, Giulio Del Vecchio, Michela Ferro, Giacomo Quattrocchio, Carla Naretto & Dario Roccatello. (2020) Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli’s regimen in membranous nephropathy. Journal of Nephrology 34:2, pages 565-571.
Crossref
Manuel Sánchez-Félix, Matt Burke, Hunter H. Chen, Claire Patterson & Sachin Mittal. (2020) Predicting bioavailability of monoclonal antibodies after subcutaneous administration: Open innovation challenge. Advanced Drug Delivery Reviews 167, pages 66-77.
Crossref
Sylvie Retout, Christophe Schmitt, Claire Petry, François Mercier & Nicolas Frey. (2020) Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A. Clinical Pharmacokinetics 59:12, pages 1611-1625.
Crossref
Mohammad Abdallah, Olivia O. Müllertz, Ian K. Styles, Alexander Mörsdorf, John F. Quinn, Michael R. Whittaker & Natalie L. Trevaskis. (2020) Lymphatic targeting by albumin-hitchhiking: Applications and optimisation. Journal of Controlled Release 327, pages 117-128.
Crossref
Jonathan S. Kingsbury, Amandeep Saini, Sarah Marie Auclair, Li Fu, Michaela M. Lantz, Kevin T. Halloran, Cesar Calero-Rubio, Walter SchwengerChristian Y. AiriauJifeng Zhang & Yatin R. Gokarn. (2020) A single molecular descriptor to predict solution behavior of therapeutic antibodies. Science Advances 6:32.
Crossref
Kip P. Conner, Siva Charan Devanaboyina, Veena A. Thomas & Dan A. Rock. (2020) The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation. Pharmacology & Therapeutics 212, pages 107574.
Crossref
Paurvi Shinde, Heather L. Howie, Tamara C. Stegmann, Ariel M. Hay, Hayley R. Waterman, Zoltan Szittner, Arthur E. H. Bentlage, Linda Kapp, Suzanne N. Lissenberg-Thunnissen, Gillian Dekkers, Richard B. M. Schasfoort, Sarah J. Ratcliffe, Mark E. Smolkin, Gestur Vidarsson, C. Ellen van der Schoot, Krystalyn E. Hudson & James C. Zimring. (2020) IgG Subclass Determines Suppression Versus Enhancement of Humoral Alloimmunity to Kell RBC Antigens in Mice. Frontiers in Immunology 11.
Crossref
Ninad Varkhede, Rupesh Bommana, Christian Schöneich & M. Laird Forrest. (2020) Proteolysis and Oxidation of Therapeutic Proteins After Intradermal or Subcutaneous Administration. Journal of Pharmaceutical Sciences 109:1, pages 191-205.
Crossref
Veena A. Thomas & Joseph P. Balthasar. (2019) Understanding Inter-Individual Variability in Monoclonal Antibody Disposition. Antibodies 8:4, pages 56.
Crossref
Amita Datta-Mannan. (2019) Mechanisms Influencing the Pharmacokinetics and Disposition of Monoclonal Antibodies and Peptides. Drug Metabolism and Disposition 47:10, pages 1100-1110.
Crossref
Patrick M. Glassman & Vladimir R. Muzykantov. (2019) Pharmacokinetic and Pharmacodynamic Properties of Drug Delivery Systems. Journal of Pharmacology and Experimental Therapeutics 370:3, pages 570-580.
Crossref
Jiahong Sun, Ruben J. Boado, William M. Pardridge & Rachita K. Sumbria. (2019) Plasma Pharmacokinetics of High-Affinity Transferrin Receptor Antibody-Erythropoietin Fusion Protein is a Function of Effector Attenuation in Mice. Molecular Pharmaceutics 16:8, pages 3534-3543.
Crossref
Felicity Kendrick, Neil D. Evans, Oscar Berlanga, Stephen J. Harding & Michael J. Chappell. (2019) Parameter Identification for a Model of Neonatal Fc Receptor-Mediated Recycling of Endogenous Immunoglobulin G in Humans. Frontiers in Immunology 10.
Crossref
Douglas Leipold & Saileta Prabhu. (2018) Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies. Clinical and Translational Science 12:2, pages 130-139.
Crossref
Xing Jing, Yan Hou, William Hallett, Chandrahas G. Sahajwalla & Ping Ji. 2019. Therapeutic Enzymes: Function and Clinical Implications. Therapeutic Enzymes: Function and Clinical Implications 115 129 .
Deni Hardiansyah & Chee Meng Ng. (2018) Minimal physiologically-based pharmacokinetic model to investigate the effect of pH dependent FcRn affinity and the endothelial endocytosis on the pharmacokinetics of anti-VEGF humanized IgG1 antibody in cynomolgus monkey. European Journal of Pharmaceutical Sciences 125, pages 130-141.
Crossref
Michael R. Turner & Sathy V. Balu-Iyer. (2018) Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins. Journal of Pharmaceutical Sciences 107:5, pages 1247-1260.
Crossref
Hanne Kinnunen Bown, Catherine Bonn, Stefan Yohe, Daniela Bumbaca Yadav, Thomas W. Patapoff, Ann Daugherty & Randall J. Mrsny. (2018) In vitro model for predicting bioavailability of subcutaneously injected monoclonal antibodies. Journal of Controlled Release 273, pages 13-20.
Crossref
Paul Malik, Colin Phipps, Andrea Edginton & Jonathan Blay. (2017) Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer. Pharmaceutical Research 34:12, pages 2579-2595.
Crossref
Lora Hamuro, Grzegorz Kijanka, Francis Kinderman, Harald Kropshofer, De-xiu Bu, Monica Zepeda & Vibha Jawa. (2017) Perspectives on Subcutaneous Route of Administration as an Immunogenicity Risk Factor for Therapeutic Proteins. Journal of Pharmaceutical Sciences 106:10, pages 2946-2954.
Crossref
Ivo P. Nnane, Chao Han, Qun Jiao, Susan H. Tam, Hugh M. Davis & Zhenhua Xu. (2017) Modification of the Fc Region of a Human Anti-oncostatin M Monoclonal Antibody for Higher Affinity to FcRn Receptor and Extension of Half-life in Cynomolgus Monkeys. Basic & Clinical Pharmacology & Toxicology 121:1, pages 13-21.
Crossref
Felicity Kendrick, Neil D. Evans, Bertrand Arnulf, Hervé Avet-Loiseau, Olivier Decaux, Thomas Dejoie, Guillemette Fouquet, Stéphanie Guidez, Stéphanie Harel, Benjamin Hebraud, Vincent Javaugue, Valentine Richez, Susanna Schraen, Cyrille Touzeau, Philippe Moreau, Xavier Leleu, Stephen Harding & Michael J. Chappell. (2017) Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma. Frontiers in Physiology 8.
Crossref
Matthew P. Kosloski, Sandra Goss, Susanne X. Wang, Jia Liu, Ralf Loebbert, Jeroen K. Medema, Wei Liu & Sandeep Dutta. (2016) Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1? and IL-1? in Healthy Subjects and Patients With Osteoarthritis of the Knee. The Journal of Clinical Pharmacology 56:12, pages 1582-1590.
Crossref
Ruben J. Boado, Eric Ka-Wai Hui, Jeff Zhiqiang Lu & William M. Pardridge. (2016) Very High Plasma Concentrations of a Monoclonal Antibody against the Human Insulin Receptor Are Produced by Subcutaneous Injection in the Rhesus Monkey. Molecular Pharmaceutics 13:9, pages 3241-3246.
Crossref
Liang Zhang, Tejas Navaratna & Greg M. Thurber. (2016) A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity. Bioconjugate Chemistry 27:7, pages 1663-1672.
Crossref
Jing Wang, Suhasini Iyer, Paul J. Fielder, John D. Davis & Rong Deng. (2015) Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development. Biopharmaceutics & Drug Disposition 37:2, pages 51-65.
Crossref
Katherine L. Gill, Iain Gardner, Linzhong Li & Masoud Jamei. (2015) A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins. The AAPS Journal 18:1, pages 156-170.
Crossref
Jiunn H. Lin & Weirong Wang. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 10 .
Weirong Wang & Thomayant Prueksaritanont. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia 1 11 .
Adriana Bajardi-Taccioli, Andrew Blum, Chongfeng Xu, Zoran Sosic, Svetlana Bergelson & Marina Feschenko. (2015) Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics. Molecular Immunology 67:2, pages 616-624.
Crossref
E. Sally Ward, Siva Charan Devanaboyina & Raimund J. Ober. (2015) Targeting FcRn for the modulation of antibody dynamics. Molecular Immunology 67:2, pages 131-141.
Crossref
Dhaval K. Shah. (2015) Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics. Journal of Pharmacokinetics and Pharmacodynamics 42:5, pages 553-571.
Crossref
Akiko Ishii-Watabe, Minoru Tada, Takuo Suzuki & Nana Kawasaki. (2015) Nonclinical Evaluation of Next-generation Therapeutic Monoclonal Antibodies次世代抗体医薬品の非臨床評価. YAKUGAKU ZASSHI 135:7, pages 857-866.
Crossref
Anas M. Fathallah, Michael R. Turner, Donald E. Mager & Sathy V. Balu-Iyer. (2015) Effects of hypertonic buffer composition on lymph node uptake and bioavailability of rituximab, after subcutaneous administration. Biopharmaceutics & Drug Disposition 36:2, pages 115-125.
Crossref
Leonid Kagan, Jie Zhao & Donald E. Mager. (2014) Interspecies Pharmacokinetic Modeling of Subcutaneous Absorption of Rituximab in Mice and Rats. Pharmaceutical Research 31:12, pages 3265-3273.
Crossref
Wolfgang F. Richter & Björn Jacobsen. (2014) Subcutaneous Absorption of Biotherapeutics: Knowns and Unknowns. Drug Metabolism and Disposition 42:11, pages 1881-1889.
Crossref
Leonid Kagan. (2014) Pharmacokinetic Modeling of the Subcutaneous Absorption of Therapeutic Proteins. Drug Metabolism and Disposition 42:11, pages 1890-1905.
Crossref
Sébastien Bihorel, Jill Fiedler-Kelly, Elizabeth Ludwig, Joanne Sloan-Lancaster & Eyas Raddad. (2014) Population Pharmacokinetic Modeling of LY2189102 after Multiple Intravenous and Subcutaneous Administrations. The AAPS Journal 16:5, pages 1009-1017.
Crossref
Tomoyuki Igawa, Atsuhiko Maeda, Kenta Haraya, Tatsuhiko Tachibana, Yuki Iwayanagi, Futa Mimoto, Yoshinobu Higuchi, Shinya Ishii, Shigero Tamba, Naoka Hironiwa, Kozue Nagano, Tetsuya Wakabayashi, Hiroyuki Tsunoda & Kunihiro Hattori. (2013) Engineered Monoclonal Antibody with Novel Antigen-Sweeping Activity In Vivo. PLoS ONE 8:5, pages e63236.
Crossref
Leonid Kagan & Donald E. Mager. (2013) Mechanisms of Subcutaneous Absorption of Rituximab in Rats. Drug Metabolism and Disposition 41:1, pages 248-255.
Crossref
Lubna Abuqayyas & Joseph P. Balthasar. (2012) Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody. International Journal of Pharmaceutics 439:1-2, pages 8-16.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.